Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot PARTUM trial of postpartum aspirin for venous thromboembolism prevention
NL-OMON50986Phase 3Completed
- Sponsor
- University of Calgary
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Aspirin with Placebo (2 arms). Primary endpoint: Symptomatic venous thromboembolism in the first 6 weeks postpartum. Started May 2023; status: completed.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON50986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50986.